Adenocarcinoma pancreas
Not yet recruitingFirst‑Line Study of Zoldonrasib (RMC‑9805) Drug Combination vs Gemcitabine/Nab‑Paclitaxel in Patients with Metastatic KRAS G12D‑Mutated Pancreatic Cancer
First‑Line Study of Zoldonrasib (RMC‑9805) Drug Combination vs Gemcitabine/Nab‑Paclitaxel in Patients with Metastatic KRAS G12D‑Mutated Pancreatic Cancer
- Disease:Adenocarcinoma pancreas
- Substances:DaraxonrasibGemcitabine
Belgium- Participants:18–64 years · 65+ years
- Substances:Daraxonrasib
- Sponsor:Revolution Medicines Inc.








